Anti-Rheumatic Rx
Bags are packed, ready to go, but wait there’s more abstracts to show.
The big news today were the “late breaking” abstracts. This is usually a favorite session of many as this is where the newest of study data often is showcased.
Here are my favorite late-breakers from Day 4.
This year at EULAR 2022, there were important and interesting topics in Axial Spondyloarthritis (AxSpA). These are my picks of abstracts from the conference.
For autoimmune patients with a history of malignancy, the initiation of biologic or targeted synthetic disease modifying agents (bDMARD/tsDMARDs) may provoke concern. While data for biologic medications and malignancy risk has been largely reassuring, clinical trials have often excluded patients with history of cancer.
Dr. Antoni Chan synovialjoints
3 years 4 months ago
Witholding MTX after both doses or only after the second dose of ChAdOx1 vaccine yields higher antibody repsonse compared to continuing MTX. Witholding MTX after second dose reduced the risk for flare. Data from MIVAC 1 and 2 #EULAR2022 @RheumNow LB https://t.co/GfL4eDXchb
Janet Pope Janetbirdope
3 years 4 months ago
Sing an ARIAA! #Bestinclass Rx of arthralgia w +MRI showed delay of #rheumatoid arthritis w #Abatacept vs #placebo. NNT to prevent 1 RA [is 8 w Rx for 1 yr & then d/c-Yrs ago #MTX delayed onset of RA but benefit waned after d/c Rx. Both ?RA spectrum POS0531 @RheumNow #EULAR2022
David Liew drdavidliew
3 years 4 months ago
72% of you would treat some high-risk subclinical arthralgias with MTX
and Marta Mosca, in the #EULAR2022 highlights, broadly agrees
OP0070 Leiden data showed better function and presenteeism. And that’s a win in my book
@RheumNow https://t.co/BqTLy4HBWR https://t.co/cwzJkH0f71
Eric Dein ericdeinmd
3 years 4 months ago
#EULAR2022 LB003: W/d MTX w COVID vax
MIVAC 1: hold MTX both vax vs continuing
MIVAC 2: hold after 2nd dose only vs continuing
⭐️MTX hold: improved Ab titers, no diff in MIVAC1/2
⭐️Higher reported flare for holding with both doses (36%) vs just 2nd dose (12%)
@Rheumnow
Richard Conway RichardPAConway
3 years 4 months ago
Kohm et al. Efficacy of IL12/23i ustekinumab independent of MTX in PsA. No additive benefit of MTX on joint, skin, QoL, function @RheumNow #EULAR2022 POS1059
Dr. Antoni Chan synovialjoints
3 years 4 months ago
Novel ePROMS use. Use of ePROMS RAPID3/PASS and asking patients if they had a flare had high diagnostic accuracy identifying those not needing DMARD or steroid intensification up and eligible to skip their next outpatient clinic visit. Seppen et al #EULAR2022 @RheumNow POS0381
David Liew drdavidliew
3 years 4 months ago
Everything's better with MTX
Controlled RA on b/tsDMARDs: can we taper MTX?
maintaining remission pooled OR 0.81 (0.68-0.97)
Unless I'm reading it wrong:
it's true many will be fine, but
keeping MTX adds benefit (even in short term, before ADAb)
POS0286 #EULAR2022 @RheumNow https://t.co/ZlwXHgACWd
Richard Conway RichardPAConway
3 years 4 months ago
Mulder et al. COMPLETE-PsA trial. MTX+LEF vs MTX mono. 78 patient RCT. LEF 20mg, MTX 25mg. MTX+LEF more effective (MDA 59% vs 32%) but less well tolerated (3 SAE vs 0; N+V, diarrhoea. No mention of LFTs). @RheumNow #EULAR2022 POS0078 https://t.co/2D84EFmabc
Richard Conway RichardPAConway
3 years 4 months ago
Frisell et al. Safety b/tsDMARDs from 10 years ARTIS. There is a mass of interesting data here, look at that figure! Higher rates of discontinuation due to AEs for tofa, bari, sari, rituximab. May be explained by chanelling and residual confounding @RheumNow #EULAR2022 POS0637 https://t.co/KrspU6c9Cs
Dr. John Cush RheumNow
3 years 4 months ago
Babies! Safety and Outcomes Data on Pregnancies
#EULAR2022 highlighted several posters on pregnancy, an important subject as most rheumatic diseases afflicts women during their childbearing years. I wanted to share with you the ones that caught my eye...
https://t.co/ulQIo2gdlO https://t.co/dpoMd5Wbah
Poster Hall